Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

ine at http://www.sec.gov, http://www.jnj.com or on request from Tibotec Pharmaceuticals Ltd. or Johnson & Johnson. Tibotec Pharmaceuticals Ltd. does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Media Contact: Pamela Van Houten

908-541-4137 (office)

908-295-7367 (mobile)

Investor Relations: Louise Mehrotra (732) 524-6491

Lesley Fishman (732) 524-3922


'/>"/>
SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email: